



State of Louisiana

Louisiana Department of Health
Office of Public Health

EMERGENCY ORDER

PROTOCOL FOR ADMINISTRATION OF MONOCLONAL ANTIBODIES FOR TREATMENT OF COVID-19 AT COMMUNITY TREATMENT SITES OPERATING UNDER CONTRACT WITH THE LOUISIANA DEPARTMENT OF HEALTH

FROM: Joseph Kanter, MD, MPH, State Health Officer

SUBJECT: EMERGENCY ORDER

PURPOSE/APPLICABILITY: To authorize Registered Nurses (RNs), while working at Community Treatment Sites for the administration of monoclonal antibodies operating under contract with the Louisiana Department of Health, to administer certain Monoclonal Antibodies for Treatment of COVID-19 by protocol in lieu of a patient-specific order from a physician or prescribing practitioner.

POLICY STATEMENT: The protocol authorized herein is intended to ensure the safety, efficacy, and increased provision of Monoclonal Antibodies for Treatment of COVID-19 to meet the needs of the public welfare.

EFFECTIVE DATES: This Emergency Order will be initially effective only until _____, 2021, but may be further extended by subsequent order of the State Health Officer. However, termination of the Public Health Emergency concerning COVID-19 originally declared by Governor John Bel Edwards in Proclamation Number 25 JBE 2020 will result in the automatic termination of this Emergency Order.

RATIONALE AND LEGAL AUTHORITY:

WHEREAS, on January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization declared the COVID-19 outbreak a “public health emergency of international concern” (PHEIC). On January 31, 2020, Health and Human Services Secretary Alex M. Azar II declared a public health emergency (PHE) for the United States. Pursuant to the Louisiana Health Emergency Powers Act, R.S. 29:760, et seq., a state of public health emergency resulting from the outbreak of “coronavirus

disease 2019” (“COVID-19”) was initially declared to exist in the entire State of Louisiana by Proclamation Number 25 JBE 2020, and was extended to the present date by subsequent declarations.

WHEREAS, Casirivimab and Imdevimab monoclonal antibodies manufactured by Regeneron Pharmaceutical, Inc. received an EUA for the treatment of COVID-19 from the FDA on November 21, 2021.

WHEREAS, Bamlanivimab and Etesevimab monoclonal antibodies manufactured by Lily Pharmaceutical, Inc. received an EUA for the treatment of COVID-19 from the FDA on February 9, 2021

WHEREAS, Sotrovimab monoclonal antibodies manufactured by GlaxoSmithKline LLC’s (GSK) received an EUA for the treatment of COVID-19 from the FDA on May 26, 2021.

WHEREAS, the Louisiana Department of Health has contracted for the operation of certain Community Treatment Sites for the administration of monoclonal antibodies throughout the state, in order to expand access to such treatment.

WHEREAS, allowing registered nurses (RNs) working at such Community Treatment Sites to administer monoclonal antibodies pursuant to a Protocol will ensure access by individuals in need of such treatment who have not received a prescription or order for treatment for monoclonal antibodies from a prescribing practitioner, and will free-up other medical resources.

WHEREAS, the SHO has determined that any risks associated with allowing registered nurses (RNs) at said Community Treatment Sites to administer certain Monoclonal Antibodies for Treatment of COVID-19 by protocol in lieu of a patient-specific order from a physician or prescribing practitioner as set forth herein is outweighed by the benefits of expanded timely administration of monoclonal antibodies to those in need thereof.

NOW THEREFORE, pursuant to the powers vested in me by La. R.S. 40:1 *et seq.*, particularly La. R.S. 40:4(A)(13) and La. R.S. 40:5(A)(1) and (2), I, Joseph Kanter, MD, MPH, State Health Officer, do hereby issue the following emergency order:

Registered nurses (RNs) licensed in Louisiana (or licensed in another jurisdiction but allowed to practice in Louisiana pursuant to Executive Order or Proclamation of the Governor, temporary approval by the appropriate Louisiana licensing board, or similar authority) are hereby authorized, while working at Community Treatment Sites for the administration of monoclonal antibodies operating under contract with the Louisiana Department of Health, to administer the above-named monoclonal antibodies pursuant to the applicable Protocols attached to this EMERGENCY ORDER, without the need for an individualized patient-specific prescription or order from a physician or other prescribing practitioner.

The authorization granted herein applies only to RNs who are competent by virtue of education and/or clinical training to safely and effectively administer the above-named monoclonal antibodies.

Signed in New Orleans, Louisiana on October _____, 2021.

Joseph Kanter, MD, MPH
State Health Officer

Concurrence:

Dr. Courtney N. Phillips DATE
LDH Secretary

ATTACHMENTS:

- LDH Protocol- Monoclonal Antibodies for Treatment of COVID-19; REGEN-COV™ (casirivimab and imdevimab); Revised 10/01/2021
- LDH Protocol- Monoclonal Antibodies for Treatment of COVID-19; Bamlanivimab and Etesevimab; Revised 10/01/2021
- LDH Protocol- Monoclonal Antibodies for Treatment of COVID-19; Sotrovimab; Revised 10/01/2021